Alto Neuroscience (NYSE:ANRO) Downgraded by Wall Street Zen to “Sell”

Alto Neuroscience (NYSE:ANRO) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other research analysts have also recently weighed in on the company. Robert W. Baird increased their price objective on Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a research report on Wednesday. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research report on Tuesday. Wedbush upped their price target on shares of Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Alto Neuroscience Price Performance

Shares of ANRO opened at $21.38 on Friday. The company’s 50-day moving average is $18.47 and its 200-day moving average is $13.60. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.42. The firm has a market capitalization of $683.04 million, a PE ratio of -9.81 and a beta of 2.52. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $25.17.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. Equities analysts forecast that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after purchasing an additional 2,055 shares in the last quarter. Peapod Lane Capital LLC increased its position in Alto Neuroscience by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after purchasing an additional 3,106 shares in the last quarter. Torren Management LLC bought a new position in Alto Neuroscience in the 4th quarter valued at approximately $62,000. XTX Topco Ltd lifted its stake in Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares during the last quarter. Finally, Citizens Financial Group Inc. RI boosted its position in Alto Neuroscience by 19.0% in the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after buying an additional 6,394 shares in the last quarter.

Alto Neuroscience News Summary

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Robert W. Baird raised its price target to $41, which can support upside sentiment and buying interest for growth/biotech investors. Robert W. Baird Boosts Alto Neuroscience (NYSE:ANRO) Price Target to $41.00
• Positive Sentiment: Wedbush reiterated a constructive outlook for Alto and flagged potential strong price appreciation, supporting demand from momentum/coverage-driven buyers. Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock
• Positive Sentiment: Chardan Capital reaffirmed its Buy rating, another supportive analyst signal for investor confidence. Chardan Capital Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)
• Neutral Sentiment: Recent quarterly report (Mar 16) slightly beat EPS consensus, which provides some fundamental support versus the negative estimate revisions. Alto Neuroscience — Company Page
• Negative Sentiment: HC Wainwright issued a broad set of downward revisions (Mar 18) to Alto’s near- and medium-term EPS: Q1 2026 to ($0.63) from ($0.59), Q2 2026 to ($0.67) from ($0.64), Q4 2026 to ($0.74) (earlier view higher), FY2026 to ($2.75) from ($2.51), and sharper cuts to FY2027–FY2029/FY2028 (e.g., FY2028 to ($4.11) from ($2.65); FY2029 to ($2.99) from ($1.54)). These more bearish earnings trajectories increase uncertainty on cash burn and timing to profitability, which likely explains much of the downward pressure on the stock today. HC Wainwright Lowers Earnings Estimates for Alto Neuroscience

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.